The American Cancer Society has updated its national prostate cancer screening guidelines in November 2026, shifting from a strictly individualized decision model to recommending routine prostate-specific antigen (PSA) blood tests for millions of men across the United States. Under the revised framework, average-risk men ages 50 through 69 are advised to undergo a PSA blood test every two years, while men at elevated risk are urged to begin annual screening earlier, according to Reuters. The organization had not updated its screening guidance since 2010, when it advised patients to weigh the potential advantages and disadvantages with a health care provider before deciding whether to be tested.

The policy revision arrives as prostate cancer continues to represent a major public health challenge in the United States, with 2026 national estimates projecting 333,830 new diagnoses and 36,320 deaths from the disease.

According to reporting from STAT and Reuters, the updated guideline reflects accumulating evidence that regular blood testing reduces deaths while modern diagnostic protocols help limit unnecessary medical procedures and treatment-related side effects.

New Age Thresholds and Risk-Based Schedules

Rather than applying a uniform schedule to all patients, the new American Cancer Society recommendation establishes specific testing intervals based on age, racial disparities, and family history. While broad summaries describe the update as routine screening for both average-risk and high-risk groups, the specific clinical schedules vary significantly by subgroup.

For men at average risk of developing prostate cancer, the guideline calls for a PSA blood test every two years starting at age 50 and continuing through age 69. However, the organization recommends annual screening starting at age 45 and continuing through age 69 for Black men.

As noted by Reuters, this earlier and more frequent schedule addresses stark clinical disparities: Black men face a 67% higher prostate cancer incidence rate and nearly double the mortality rate compared with white men.

Annual PSA testing is also recommended for men who have a family history of prostate cancer, though initial summary reports of the guideline did not specify which degree of relative or age at diagnosis qualifies a patient for this elevated-risk schedule. Even with the transition toward routine testing, the new guidance retains the requirement that clinicians counsel patients on the potential benefits and harms of screening before drawing blood.

Safeguards Against Overdiagnosis and Overtreatment

Historically, medical organizations hesitated to endorse widespread, routine PSA testing because elevated antigen levels do not always indicate a dangerous malignancy. An abnormal test result often initiated an aggressive diagnostic cascade, leading to invasive prostate biopsies and the detection of slow-growing tumors that would never have caused symptoms or threatened a patient's life.

Subsequent surgeries or radiation therapies frequently left patients with lasting complications, including urinary incontinence and erectile dysfunction.

According to Reuters, the American Cancer Society altered its assessment of the benefit-to-harm balance largely because modern urological care has introduced protective steps between an initial blood test and invasive intervention. Under the updated guideline, a single elevated PSA result should not immediately trigger a tissue biopsy. Instead, the protocol calls for a repeat PSA blood test and a magnetic resonance imaging (MRI) scan prior to scheduling a biopsy.

When testing does identify a low-risk prostate cancer, the guideline recommends initially offering close monitoring—commonly known as active surveillance—rather than immediate surgery or radiation. This approach aligns with international diagnostic standards.

According to the European Association of Urology, the primary objective of modern evaluation pathways is to detect clinically significant prostate cancer while leaving insignificant disease undisturbed, balancing diagnostic accuracy with patient well-being and health care resources.

How National and International Guidelines Compare

The American Cancer Society's shift creates a notable contrast with other major health bodies in the United States and abroad. According to reporting by medical journalist Howard Wolinsky, the U.S. Preventive Services Task Force (USPSTF)—an independent federal panel whose grades determine preventive insurance coverage requirements under the Affordable Care Act—continues to operate under its 2018 recommendation while an update remains in progress.

That 2018 USPSTF policy assigns a Grade C to PSA screening for men ages 55 to 69, meaning the panel does not recommend routine testing for all men in that bracket, but instead advises that the choice to screen should be an individual one after discussing benefits and harms with a doctor.

For men age 70 and older, the federal task force recommends against PSA-based screening altogether. The task force had previously issued a blanket Grade D recommendation against PSA screening for all age groups in 2012, a stance the American Urological Association criticized at the time before the panel softened its position six years later.

Meanwhile, European clinical standards take a risk-adapted approach similar to the new American Cancer Society framework. According to the European Association of Urology, informed early PSA testing is recommended starting at age 50 for average-risk men, at age 45 for men of African descent or those with a family history of the disease, and at age 40 for men carrying BRCA2 genetic mutations.

Navigating Screening Decisions After Age 70

While prostate cancer is predominantly a disease of older men—approximately six in 10 cases are diagnosed at age 65 or older, with an average diagnosis age of about 68, according to AARP—the updated American Cancer Society guideline does not endorse automatic screening for seniors beyond age 69.

Instead, the recommendations introduce specific age and life-expectancy limits to prevent unnecessary medical burdens in older populations:

  • Ages 70 to 74: Men in this age bracket should discuss with a clinician whether to continue or initiate testing, as the balance between clinical benefits and potential harms remains uncertain.
  • Ages 75 to 79: Routine screening is generally not recommended from age 75 onward, though the guideline notes a possible exception for exceptionally healthy men between 75 and 79, particularly if prior testing showed a rising PSA level.
  • Age 80 and Older: Screening is not recommended for men age 80 and above, nor is it advised for any patient with a life expectancy of less than 10 years.

Frequently Asked Questions

Why are repeat blood tests and MRI scans recommended before a biopsy?

PSA levels can fluctuate due to benign conditions such as prostate inflammation or enlargement. Requiring a repeat blood test and an MRI scan before an invasive biopsy helps doctors filter out false-positive results, avoid biopsy complications, and focus tissue sampling on suspicious areas that are more likely to harbor aggressive cancer.

How should men in their 70s weigh the decision to get screened?

Because localized prostate cancer typically grows very slowly, older men are less likely to experience life-extending benefits from early detection and more likely to experience complications from biopsies or treatments. Men ages 70 to 74—and exceptionally healthy men ages 75 to 79—should evaluate their overall health status, prior PSA trends, and whether they have at least a 10-year life expectancy when discussing testing with their physician.

Sources